InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.